Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. (Q51572280)

7 April 2018

title

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. (English)

1 reference

7 April 2018

0 references

1 reference

1 reference

Garber AJ

1

1 reference

7 April 2018

Duncan TG

2

1 reference

7 April 2018

Goodman AM

3

1 reference

7 April 2018

Mills DJ

4

1 reference

7 April 2018

Rohlf JL

5

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 December 1997

1 reference

7 April 2018

American Journal of Medicine

published in

1 reference

7 April 2018

volume

103

1 reference

7 April 2018

issue

6

1 reference

7 April 2018

page(s)

491-497

1 reference

7 April 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Cellular mechanism of action of metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

The comparison of several dose levels with a zero dose control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

What is the benefit of increasing the sulfonylurea dose?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900254-4

10.1016/S0002-9343(97)00254-4

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

9428832

1 reference

7 April 2018